A pilot observation series was conducted on patients with chronic, non-healing wounds (including HS, pressure injury). Each patient had received standard wound care and/or systemic therapies with minimal improvement prior to ON101 initiation. Daily topical application was performed by clinicians or caregivers. Clinical parameters tracked included:
Both cases demonstrated rapid healing and improvement post-ON101 application.
No adverse effects reported; all patients tolerated ON101 well.
ON101 may enhance local wound environments by modulating macrophage polarization and promoting tissue regeneration. Its role in managing HS and other atypical wounds that are stalled despite standard care highlights its potential as a versatile topical adjunct, especially in patients with systemic risk factors (e.g., steroids, immobility, vascular disease).
This case series illustrates the potential of ON101 in promoting wound resolution across diverse and difficult-to-treat wound types, including HS, and pressure injuries. Rapid responses observed in previously stalled wounds warrant further investigation through larger prospective studies.
Hidradenitis Suppurativa (HS) is a chronic inflammatory skin disorder often refractory to standard treatments. Beyond HS, a subset of atypical and stalled wounds—such as pressure injuries—also pose persistent healing challenges. ON101, a macrophage-regulating topical cream, has been evaluated in several stalled or non-healing wounds at Woundtech. This poster presents a case series highlighting ON101’s potential role in managing both HS and other atypical wound types.